Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is a late-stage clinical biotechnology company developing innovative nanoparticle-based therapies for cancer treatment, with lead program NBTXR3 showing promising results in Phase II/III trials for soft-tissue sarcoma and in ongoing Phase III trials for elderly, cisplatin-ineligible patients with locally advanced squamous-cell carcinoma of the head and neck (LA HNSCC). The company's collaboration with JNJ and the potential for significant royalties and milestones adds to the positive outlook, although risks such as clinical trial failures and regulatory setbacks should be considered. The company is also facing financial risks, with meaningful debt on its balance sheet and potential need for additional financing before turning cash flow positive.

Bears say

Nanobiotix is a late-stage clinical biotechnology company with a promising pipeline and strong operational progress. However, the company's novel radioenhancer, NBTXR3, presents clinical and commercial risks and the data is still in the early stages. There are upcoming milestones and catalysts to keep an eye on, but overall, the company's cash runway is extended into 2029, providing some stability.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Sep 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.